Haleon (HLN) Non-Current Assets (2021 - 2026)
Haleon's (HLN) quarterly Non-Current Assets came in at $38.0 billion in Q2 2026, up 0.89% on a QoQ basis from $37.6 billion in Q4 2025.
Haleon (HLN) Non-Current Assets (2021 - 2026) Analysis & Trends
Haleon (HLN) has 6 years of Non-Current Assets data on file, last reported at $38.0 billion in Q2 2026.
- Quarterly Non-Current Assets changed N/A year-over-year to $38.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $38.0 billion (changed N/A YoY) and the FY2025 annual result came in at $37.4 billion, up 3.61% from the prior year.
- Non-Current Assets climbed to $38.0 billion in Q2 2026, from $37.6 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $38.5 billion in Q2 2022 to a low of $35.8 billion in Q4 2023.
- A 5-year average of $37.0 billion and a median of $36.9 billion in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets retreated 8.35% — and 2025, when it climbed 3.93%.
- Tracing HLN's Non-Current Assets over 5 years: stood at $36.1 billion in 2022, then fell by 0.67% to $35.8 billion in 2023, then gained by 1.02% to $36.2 billion in 2024, then rose by 3.93% to $37.6 billion in 2025, then rose by 0.89% to $38.0 billion in 2026.
- The last three Non-Current Assets figures came in at $38.0 billion (Q2 2026), $37.6 billion (Q4 2025), and $36.2 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | 2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.96 Bn |
| Dec 31, 2025 | 37.62 Bn |
| Dec 31, 2024 | 36.20 Bn |
| Jun 30, 2024 | 36.21 Bn |
| Dec 31, 2023 | 35.83 Bn |
| Jun 30, 2023 | 37.49 Bn |
| Dec 31, 2022 | 36.07 Bn |
| Jun 30, 2022 | 38.54 Bn |
| Dec 31, 2021 | 39.36 Bn |